Vical presents Leuvectin and Allovectin data
Interim data from 37 of 61 patients in VICL's Phase II trial of Leuvectin showed that tumor burden was reduced in 3 of 21 patients with limited metastatic kidney cancer and mild symptoms. The duration of these responses is 12-19 weeks and ongoing. An additional 6 patients have stable disease lasting from 19-69 weeks and ongoing. In patients with multiple sites and symptoms of the cancer, 6 of 16 experienced stable disease lasting 18-30 weeks, with none achieving 50 percent reduction in total tumor burden. Leuvectin, a gene encoding interleukin-2 (IL-2) injected directly into tumors, was well tolerated with four adverse events requiring overnight hospital stays.
The company began a second Phase II trial to treat limited metastatic disease and minimal symptoms using 6 weekly 4 mg doses. VICL also received orphan drug designation for Leuvectin to treat metastatic kidney cancer. ...